← Back to Search

Inflammasome Inhibitor

Dapansutrile for Heart Attack Recovery

Phase < 1

Waitlist Available

Research Sponsored by University of Virginia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Carotid or femoral artery plaque at baseline, or carotid intima media thickness >1.5 mm

Reperfusion therapy planned or performed within prior 48 hrs

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial will look at the effects of an oral inflammation inhibitor on plaque volume, inflammation and microvascular function in those who have had a heart attack.

Who is the study for?

This trial is for individuals who have had a type I heart attack and received reperfusion therapy within the last 48 hours. They must have certain levels of artery plaque or thickness to join. People with severe kidney issues, recent strokes, allergies to specific agents, pregnancy, life-threatening complications from their heart attack, certain infections or cancers can't participate.Check my eligibility

What is being tested?

The study tests if dapansutrile (an inflammasome inhibitor) affects carotid plaque volume over six months compared to a placebo in patients after an urgent heart attack treatment. It also looks at inflammation in plaques and how well small blood vessels in the heart are working.See study design

What are the potential side effects?

Potential side effects of dapansutrile may include allergic reactions for those sensitive to it or its class of drugs. Since this is a new area of research, participants will be closely monitored for any unexpected side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have plaque in my carotid or femoral artery, or my carotid artery wall is thick.

Select...

I have had or am scheduled for a procedure to restore blood flow within the last 2 days.

Select...

I have had a recent heart attack.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Remote plaque volume

Secondary outcome measures

Coronary microvascular function

Plaque inflammation

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: DapansutrileExperimental Treatment1 Intervention

Subjects randomized to receive oral dapnsutrile

Group II: ControlPlacebo Group1 Intervention

Subjects randomized to receive oral placebo

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of VirginiaLead Sponsor

753 Previous Clinical Trials

1,244,971 Total Patients Enrolled

Media Library

Dapansutrile (Inflammasome Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05880355 — Phase < 1

Heart Attack Research Study Groups: Dapansutrile, Control

Heart Attack Clinical Trial 2023: Dapansutrile Highlights & Side Effects. Trial Name: NCT05880355 — Phase < 1

Dapansutrile (Inflammasome Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05880355 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial encompass participants of over four decades in age?

"Patients aged between 18 and 90 are currently being accepted into this trial."

Answered by AI

Are there any available openings for participants in this clinical trial?

"Per the information posted on clinicaltrials.gov, this specific trial is no longer recruiting patients. Its original posting date was January 1st 2022 and its last update was May 19th 2023; however, there are currently 341 other trials actively enlisting participants."

Answered by AI

Would I be a suitable candidate for this trial?

"Inclusion criteria for this research necessitate that potential participants must have been affected by a heart attack and be situated between the ages of 18 and 90. This clinical trial is open to up to 60 patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation

Jonathan Lindner, MD 2024. "Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05880355.

All > Heart Attack